ReproCELL, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3974770004
JPY
176.00
2 (1.15%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor Management Efficiency with a low ROE of 0.31%

  • The company has been able to generate a Return on Equity (avg) of 0.31% signifying low profitability per unit of shareholders funds
2

With a fall in Net Sales of -15.05%, the company declared Very Negative results in Dec 25

3

Risky -

4

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

JPY 16,211 Million (Small Cap)

stock-summary
P/E

160.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.66

stock-summary
Return on Equity

-3.21%

stock-summary
Price to Book

1.87

Revenue and Profits:
Net Sales:
636 Million
(Quarterly Results - Dec 2025)
Net Profit:
27 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
22.22%
0%
22.22%
6 Months
-12.0%
0%
-12.0%
1 Year
17.33%
0%
17.33%
2 Years
11.39%
0%
11.39%
3 Years
-26.67%
0%
-26.67%
4 Years
-22.47%
0%
-22.47%
5 Years
-57.38%
0%
-57.38%

ReproCELL, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
19.94%
EBIT Growth (5y)
13.17%
EBIT to Interest (avg)
-518.22
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.44
Sales to Capital Employed (avg)
0.32
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0.31%

Valuation key factors

Factor
Value
P/E Ratio
160
Industry P/E
Price to Book Value
1.84
EV to EBIT
-96.27
EV to EBITDA
-157.51
EV to Capital Employed
2.49
EV to Sales
4.21
PEG Ratio
0.81
Dividend Yield
NA
ROCE (Latest)
-2.59%
ROE (Latest)
1.15%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -15.06% vs 18.87% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -62.57% vs 685.60% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "635.70",
          "val2": "748.40",
          "chgp": "-15.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-111.00",
          "val2": "-17.00",
          "chgp": "-552.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "27.40",
          "val2": "73.20",
          "chgp": "-62.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-203.90%",
          "val2": "-41.50%",
          "chgp": "-16.24%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 22.74% vs -17.83% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 428.66% vs 89.72% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,978.60",
          "val2": "2,426.80",
          "chgp": "22.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-79.70",
          "val2": "-372.20",
          "chgp": "78.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-63.70",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "103.20",
          "val2": "-31.40",
          "chgp": "428.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-43.80%",
          "val2": "-168.70%",
          "chgp": "12.49%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
635.70
748.40
-15.06%
Operating Profit (PBDIT) excl Other Income
-111.00
-17.00
-552.94%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
27.40
73.20
-62.57%
Operating Profit Margin (Excl OI)
-203.90%
-41.50%
-16.24%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2025 is -15.06% vs 18.87% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -62.57% vs 685.60% in Dec 2024

Annual Results Snapshot (Consolidated) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
2,978.60
2,426.80
22.74%
Operating Profit (PBDIT) excl Other Income
-79.70
-372.20
78.59%
Interest
0.00
0.00
Exceptional Items
0.00
-63.70
100.00%
Consolidate Net Profit
103.20
-31.40
428.66%
Operating Profit Margin (Excl OI)
-43.80%
-168.70%
12.49%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 22.74% vs -17.83% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 428.66% vs 89.72% in Mar 2024

stock-summaryCompany CV
About ReproCELL, Inc. stock-summary
stock-summary
ReproCELL, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available